Trials / Terminated
TerminatedNCT04182516
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
A Phase I Dose Escalation Study of NMS-03305293 in Adult Patients with Selected Advanced/Metastatic Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Nerviano Medical Sciences · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in adult patients with selected advanced/metastatic, relapsed/refractory solid tumors who have exhausted standard treatment options or for whom standard therapy is considered unsuitable.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NMS-03305293 | All patients will receive NMS-03305293 administered orally on Days 1-21 (schedule A) or Days 1-28 (schedule B) in repeated 4-week cycles. |
Timeline
- Start date
- 2019-11-25
- Primary completion
- 2023-03-31
- Completion
- 2024-05-16
- First posted
- 2019-12-02
- Last updated
- 2024-09-19
Locations
10 sites across 5 countries: United States, Bulgaria, China, Italy, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04182516. Inclusion in this directory is not an endorsement.